Study Showing Remdesivir Doesn’t Prevent Death Could Impact Drug’s Price

By Ariel Cohen, John Wilkerson / October 20, 2020 at 4:25 PM
Editors' Note: After this story was published, FDA approved remdesivir to treat hospitalized COVID-19 patients 12 and over. A new World Health Organization-funded study that found remdesivir may not reduce mortality from COVID-19 could put pressure on its maker, Gilead, to cut the price of the antiviral, which is the only pandemic drug to receive an emergency use authorization. Remdesivir did not reduce the death rate or length of hospital stays among COVID-19 patients in the large...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.